Evry, France-Neurotech will refocus its efforts on ophthalmic technologies, halting research and development activities in the fields of neuroscience and cell therapy.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.